Logo

SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology

Share this
SeaStar Medical

SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology

Shots:

  • SeaStar Medical has received patent no. 2814586 by the Canadian Intellectual Property Office for its Selective Cytopheretic Device (SCD) technology
  • The Canadian patent, titled Cytopheretic Cartridge and Use Thereof, claims coverage of SCD cartridges for the treatment of activated leukocytes & activated platelets and their utilization in processing activated leukocytes and platelets
  • The SCD technology employs the body’s immune system to heal and can be used with extracorporeal therapies incl. dialysis or continuous kidney replacement therapy. It targets toxic neutrophils to offer a new approach to systemic inflammatory response syndrome

Ref: Seastar | Image: Seastar

Related News:- SeaStar Medical Signed US License and Distribution Agreement with Nuwellis for Selective Cytopheretic Device to Treat Acute Kidney Injury in Pediatric Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions